Samsung Medison showcases liver diagnostic solutions at KCR 2026

Samsung Medison announced Wednesday that it will showcase a range of imaging diagnostic solutions at the Korean Society of Radiology's annual conference, KCR 2026. The solutions are designed to support physicians' diagnoses and ease examination burdens through precise imaging, quantitative analysis and automation technology.

KCR 2026 runs from Wednesday through Saturday at Kintex in Goyang. Samsung Medison is focusing on the value imaging technology can bring to physicians and patients in real clinical settings.

To that end, the company outlined three key technology directions. The first is precise imaging and quantitative technology that supports accurate diagnosis. The second is automated diagnostic assistance features that reduce variability stemming from an examiner's skill level. The third is an efficient examination environment that shortens exam times to ease the burden on both physicians and patients.

In particular, the company is spotlighting its "Liver Total Solution," centered on its premium ultrasound diagnostic device for radiology, the R20. The R20 allows a single device to comprehensively assess a range of liver characteristics, from fatty liver to fibrosis and tissue viscosity.

Its flagship technology, DeepUSFF, a deep learning-based fatty liver quantification tool, showed a strong correlation with MRI-PDFF, the standard for diagnosing fatty liver, in clinical validation using global multicenter patient data. It achieved diagnostic accuracy exceeding 90 percent across mild, moderate and severe fatty liver stages, pointing to the potential for more objective and consistent quantitative assessment of fatty liver.

Samsung Medison also improved examination efficiency in liver fibrosis assessment through automation. EzSWI automatically designates a region of interest to minimize examiner intervention while measuring liver stiffness. According to a research team led by Professor Lee Jeong-min of Seoul National University Hospital's Department of Radiology, using EzSWI cuts exam time by about 55 percent compared with conventional methods. The technique showed no significant difference in diagnostic accuracy, and is expected to reduce the time patients spend undergoing exams.

Adding S-Viscosity, a technology that measures viscosity-related characteristics of liver tissue, the R20 provides a multiparameter-based liver ultrasound assessment environment that evaluates fat, fibrosis and viscosity together.

This goes beyond measuring individual figures — by comprehensively capturing various characteristics of liver disease within a single examination environment, it helps physicians make more reliable clinical judgments.

The R20's clinical value will also be presented at a luncheon symposium on Thursday. Professor Lee Jeong-min of Seoul National University Hospital's Department of Radiology is scheduled to give a presentation titled "Multiparametric Liver Ultrasound: Expanding from Fibrosis to Fat and Viscosity Mapping."

Beyond liver disease, Samsung Medison is also presenting specialized solutions for other major radiology fields — including breast, thyroid, musculoskeletal and urological imaging — aimed at improving diagnostic accuracy and examination efficiency.

Cho Young-beom, head of Samsung Medison's domestic sales team, said, "The advancement of imaging technology should go beyond simply offering more features — it must help physicians make more reliable judgments and allow patients to undergo exams more efficiently." He added, "Going forward, we will continue to expand our imaging diagnostic solutions based on feedback from clinical settings and verified data, in order to deliver real value to both physicians and patients."